Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeting epithelium-expressed sialyl Lewis glycans improves colonic mucosal wound healing and protects against colitis
Matthias Kelm, Miguel Quiros, Veronica Azcutia, Kevin Boerner, Richard D. Cummings, Asma Nusrat, Jennifer C. Brazil, Charles A. Parkos
Matthias Kelm, Miguel Quiros, Veronica Azcutia, Kevin Boerner, Richard D. Cummings, Asma Nusrat, Jennifer C. Brazil, Charles A. Parkos
View: Text | PDF
Research Article Immunology Inflammation

Targeting epithelium-expressed sialyl Lewis glycans improves colonic mucosal wound healing and protects against colitis

  • Text
  • PDF
Abstract

Dysregulated healing of injured mucosa is a hallmark of many pathological conditions, including inflammatory bowel disease. Mucosal injury and chronic intestinal inflammation are also associated with alterations in epithelial glycosylation. Previous studies have revealed that inflammation-induced glycan sialyl Lewis A on epithelial CD44v6 acts as a ligand for transmigrating PMNs. Here we report that robust sialylated Lewis glycan expression was induced in colonic mucosa from individuals with ulcerative colitis and Crohn disease as well as in the colonic epithelium of mice with colitis induced by dextran sodium sulfate (DSS). Targeting of sialylated epithelial Lewis glycans with mAb GM35 reduced disease activity and improved mucosal integrity during DSS-induced colitis in mice. Wound healing studies revealed increased epithelial proliferation and migration responses as well as improved mucosal repair after ligation of epithelial sialyl Lewis glycans. Finally, we showed that GM35-mediated increases in epithelial proliferation and migration were mediated through activation of kinases that signal downstream of CD44v6 (Src, FAK, Akt). These findings suggest that sialylated Lewis glycans on CD44v6 represent epithelial targets for improved recovery of intestinal barrier function and restitution of mucosal homeostasis after inflammation or injury.

Authors

Matthias Kelm, Miguel Quiros, Veronica Azcutia, Kevin Boerner, Richard D. Cummings, Asma Nusrat, Jennifer C. Brazil, Charles A. Parkos

×

Figure 4

Targeting of sialyl Lewis glycans on CD44v6 with GM35 increases migration and proliferation of human epithelial cells.

Options: View larger image (or click on image) Download as PowerPoint
Targeting of sialyl Lewis glycans on CD44v6 with GM35 increases migratio...
(A) Percentage of intestinal epithelial wound closure was calculated by measuring wound widths at 12, 18, and 24 hours after wounding. IECs were incubated with 10 μg/mL GM35, NS19-9, anti-CD44v6 mAb, or IgG matched control antibody. Data are shown as mean ± SEM and were analyzed by 1-way ANOVA followed by Tukey’s post hoc testing (n = 4 experiments, 6 wounds per treatment), *P < 0.05, **P < 0.01. (B) Immunofluorescence staining of scratch-wounded T84 IECs with mAb GM35 in green and anti-CD44v6 mAb in red. Scale bar: 20 μm. (C) Wound closure after 24 hours was measured in colonoid-derived primary human epithelial cells after treatment with 10 μg/mL GM35 or an IgG matched control mAb. Data are shown as mean ± SEM analyzed by 1-way ANOVA followed by Tukey’s post hoc testing (black and red circles represent averages of n = 5 experiments, 6 wounds per group per experiment), **P < 0.01. (D) Scratch-wounded intestinal epithelial monolayers were treated with 10 μg/mL GM35, NS19-9, or control IgG before EdU incorporation was measured 18 hours after injury. Scale bar: 5 μm. (E) Quantification of proliferation/EdU incorporation. Data are shown as mean ± SEM analyzed by 1-way ANOVA followed by Tukey’s post hoc testing (circles represent averages of n = 3 experiments, 5 wounds per treatment); **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts